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AbsTRACT
Objectives To compare the efficacy and safety of 
topical non-steroidal anti-inflammatory drugs (NSAIDs), 
including salicylate, for the treatment of osteoarthritis 
(OA).
Methods PubMed, Embase, Cochrane Library and Web 
of Science were searched from 1966 to January 2017. 
Randomised controlled trials (RCTs) comparing topical 
NSAIDs with placebo or each other in patients with OA 
and observational studies comparing topical NSAIDs 
with no treatment or each other irrespective of disease 
were included. Two investigators identified studies and 
independently extracted data. Bayesian network and 
conventional meta-analyses were conducted. The primary 
outcomes were pain relief for RCTs and risk of adverse 
effects (AEs) for observational studies.
Results 43 studies, comprising 36 RCTs (7 900 patients 
with OA) and seven observational studies (218 074 
participants), were included. Overall, topical NSAIDs 
were superior to placebo for relieving pain (standardised 
mean difference (SMD)=−0.30, 95% CI −0.40 to –0.20) 
and improving function (SMD=−0.35, 95% CI −0.45 to 
–0.24) in OA. Of all topical NSAIDs, diclofenac patches 
were most effective for OA pain (SMD=−0.81, 95% CI 
−1.12 to –0.52) and piroxicam was most effective for 
functional improvement (SMD=−1.04, 95% CI −1.60 to 
–0.48) compared with placebo. Although salicylate gel 
was associated with higher withdrawal rates due to AEs, 
the remaining topical NSAIDs were not associated with 
any increased local or systemic AEs.
Conclusions Topical NSAIDs were effective and safe 
for OA. Diclofenac patches may be the most effective 
topical NSAID for pain relief. No serious gastrointestinal 
and renal AEs were observed in trials or the general 
population. However, confirmation of the cardiovascular 
safety of topical NSAIDs still warrants further 
observational study.
InTROduCTIOn
Osteoarthritis (OA) is a major source of pain, 
disability and socioeconomic costs worldwide1 
and commonly affects footballers, rugby players 
and other athletes.2–4 Oral non-steroidal anti-in-
flammatory drugs (NSAIDs) are recommended 
for OA pain,5–10 but their safety concerns often 
outweigh their benefits.11 Concerns over the gastro-
intestinal (GI) risk of oral traditional NSAIDs are 
widely accepted,12 and selective cyclooxygenase-2 
(COX-2) inhibitors were developed as an alterna-
tive to reduce this risk. COX-2 inhibitors, however, 
are associated with an increased risk of cardiovas-
cular (CV) events.13–17 It is therefore suggested that 
both oral NSAIDs and COX-2 inhibitors should be 
prescribed with a proton pump inhibitor in patients 
with a high risk of GI bleeding.18–20 However, the 
issues associated with polypharmacy and the addi-
tional costs of this combination therapy limit their 
use.21 
Topical NSAIDs offer an alternative to decrease 
the risk of systemic NSAIDs.22 Although topical 
NSAIDs are considered relatively safe, their skin 
adverse effects (AEs) cannot be ignored (ranging 
from 10% to 39%).23 24 With respect to systemic 
AEs, GI bleeding, dyspepsia, acute renal impair-
ment and asthma have been reported in relation 
to topical NSAIDs.25–27 Furthermore, the preva-
lence of systemic AEs in the older population has 
been reported to be as high as 17.5%, of which 
2%–9% may be GI AEs.24 However, these studies 
did not have control groups and the risk cannot 
be wholly attributed to the use of topical NSAIDs. 
Therefore, the safety profile of topical NSAIDs 
remains unclear.
The Osteoarthritis Research Society International 
guidelines consider topical NSAIDs to be safer and 
better tolerated than oral NSAIDs in knee OA.6 
In UK, the National Institute for Health and Care 
Excellence (NICE) recommend topical NSAIDs 
ahead of systemic analgesics (ie, paracetamol, oral 
NSAIDs, COX-2 inhibitors and opioids) for knee 
and hand OA.5 In 2004, we conducted a conven-
tional meta-analysis and found that topical NSAIDs 
were effective for OA pain, but the efficacy only 
remained significant in the first 2 weeks of appli-
cation when compared with placebo.28 Due to 
the limited number of trials (13) included at the 
time, the results may not be conclusive. More 
recently, a meta-analysis of 215 trials reported 
that topical NSAIDs exhibited the largest overall 
treatment effect (ie, specific treatment effect plus 
contextual effect) for pain relief in OA among 11 
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representative treatments, including complementary, phar-
macological, non-pharmacological and surgical treatments.29 
Although recommended and known to be effective, it is still a 
challenge to choose a particular topical NSAID when faced with 
so many available options that vary in terms of the contained 
NSAID, carrier and mode of application (eg, cream, gel and 
patch).
A recent Cochrane systematic review examined the efficacy 
and safety of topical NSAIDs in chronic musculoskeletal pain.30 
However, it was not specific to OA and could not compare the 
relative efficacy between topical NSAIDs as it was not a network 
meta-analysis. Furthermore, it used only randomised controlled 
trials (RCTs) for safety assessment. RCTs are only relevant 
for AEs with a high incidence, while observational studies are 
required for AEs that occur with moderate-low incidence and 
that require longer term to occur.
We undertook this systematic review and network meta-anal-
ysis of RCTs and observational studies and have ranked the 
topical NSAIDs (including salicylate) based on the results.
MeThOds
Literature search
Systematic literature searches were undertaken using PubMed, 
Embase, Cochrane Library and Web of Science. Search strategies, 
using a series of keywords related to topical NSAIDs (including 
salicylate), formulations and study designs, were used to identify 
relevant RCTs in patients with OA and relevant observational 
studies in any condition (online supplementary appendix 1) from 
1966 to January 2017. The database search was supplemented by 
subsequent periodic scrutiny of unpublished and ongoing RCTs 
from the WHO International Clinical Trials Registry (ICTRP) 
(http:// apps. who. int/ trialsearch/). In addition, references of the 
retrieved papers and reviews were manually reviewed.
Inclusion/exclusion criteria
The inclusion criteria for RCTs were as follows: (1) RCTs; (2) 
studies on patients with OA at any joint; (3) studies comparing 
topical NSAIDs (including salicylate) with placebo or each other; 
(4) studies reporting pain, function or AE outcomes in patients 
and (5) studies published in any language. The following studies 
were excluded: (1) secondary analyses, including some combined 
data analyses of published RCTs; (2) studies where the follow-up 
time was less than 1 week; (3) cross-over design studies; (4) 
topical NSAIDs combined with other drugs; (5) studies for post-
operative pain and (6) abstract only (insufficient data).
The inclusion criteria for observational studies were as 
follows: (1) observational studies (case-control, nested case-con-
trol, cross-sectional, cohort or longitudinal studies); (2) studies 
comparing topical NSAIDs (including salicylate) with no treat-
ment or each other; (3) studies reporting any AE outcomes in 
humans and (4) studies published in any language. The following 
studies were excluded: (1) ophthalmological conditions and (2) 
abstract only.
Quality assessment
The Cochrane risk of the bias assessment tool was used to 
determine the methodological quality of RCTs.31 A total of six 
domains were evaluated: random sequence generation, allo-
cation concealment, participant blinding, outcome assessor 
blinding, incomplete outcome data and selective reporting. Each 
domain was assigned a judgement of low risk of bias, high risk 
of bias or unclear risk of bias. The judgments for each domain 
were made strictly following the Cochrane Handbook V.5.1.0, 
Chapter 8.5.31
The methodological quality of the observational studies was 
evaluated using the Newcastle-Ottawa Scale (NOS),32 which was 
developed to assess the quality of non-randomised studies based 
on three broad domains: selection of the study groups, compa-
rability among different groups and ascertainment of either the 
exposure or outcome of interest. The total score of NOS ranges 
from 0 to 9 based on its assessment items.
Outcome measures
For RCTs, the primary outcome was pain relief. The secondary 
outcome was functional improvement. The change-from-base-
line score at the last follow-up period was used/calculated. If a 
study reported multiple pain scales, the scale with the highest 
sensitivity to change was used.33 The function subscale of 
Western Ontario and McMaster Universities Arthritis Index 
(WOMAC) was used for the assessment of functional improve-
ment. If a study did not measure or report WOMAC function, 
the Lequesne Index or one of the other functional measurement 
scales was used instead. If the original paper was unavailable/
unpublished, the outcomes were extracted from systematic 
reviews and meta-analyses, if available.30 If a study involved 
multiple treatment groups with different doses of the same drug, 
the data were combined into one treatment group. Only differ-
ences between two treatment arms were calculated. As different 
scales were used for the same outcome, the standardised mean 
difference (SMD) was calculated.31
To determine the safety and tolerability of topical NSAIDs, 
data from both RCTs and observational studies were analysed 
separately. The number of participants who experienced any AE 
(including local, GI, CV and renal AEs) and withdrawals due to 
AEs were calculated per group. The adjusted OR for any AE was 
derived for the safety of topical NSAIDs versus placebo/control. 
If unavailable, the crude OR was selected instead.
statistical analysis
A conventional meta-analysis was conducted to compare topical 
NSAIDs overall with placebo (in RCTs) and with no treatment 
(in observational studies). The heterogeneity of the effect size 
across the studies was tested using the Q statistic (P<0.05 was 
considered heterogeneous) and I2 statistic (I2 >50% was consid-
ered heterogeneous). If there was significant heterogeneity 
between studies, a random-effects model was used; otherwise, 
a fixed-effects model was used. Subgroup analyses of topical 
NSAIDs versus placebo at different follow-up periods (week 1 to 
week 4 and over 4 weeks) were conducted.
The Bayesian network meta-analysis methods have been 
described in our previous research.15 16 34 35 The methods used can 
increase the number of studies within each comparison, thereby 
narrowing the width of the CI of the estimate.36–40 The Markov 
Chain Monte Carlo method was used to estimate posterior 
densities for unknown variables.39 41 42 A random effects model 
was adopted as the most appropriate and conservative analysis 
method to assess differences between trials. Two Markov chains 
ran simultaneously with different initial values, which were 
chosen arbitrarily for convergence. A total of 50 000 simulations 
were generated for each of the two sets of initial values, and 
the first 10 000 simulations were discarded due to the burn-in 
period. The WinBUGS codes are available at http://www. bristol. 
ac. uk/ social- community- medicine/ projects/ mpes/ (online supple-
mentary appendix 2). The overall effect sizes (SMDs or ORs) 
were generated from the median of the posterior distribution. 
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The 2.5th and 97.5th percentiles of the posterior distribution 
were considered the lower and upper limit, respectively, of the 
traditional corresponding 95% CI. Significant differences were 
identified when the 95% CI did not include 0 for SMD or 1 for 
OR. Heterogeneity was defined as the variability of results across 
trials, with τ2<0.04 indicating a low level and τ2>0.4 a high 
level.43 When trials contained three or more treatment arms, 
inconsistency was defined by the differences between direct and 
indirect effect estimates for the same comparison.44 The fit of 
the model to the data was measured by calculating the posterior 
mean residual deviance.45 Rankings for all evaluated treatments 
were based on the level of effect according to their posterior 
probabilities. Surface under the cumulative ranking (SUCRA) 
is equal to 100% for the best treatment and 0% for the worst 
treatment.44 46 Subgroup analyses were conducted by restricting 
studies to only those who enrolled knee OA or hand OA partic-
ipants, to non-commercially funded studies and to studies with 
efficacy data at 1 or 2 weeks. Network meta-regressions were 
conducted to consider the potential impact of pain and func-
tion level at baseline, length of follow-up time and treatment 
duration.47–49
All statistical analyses were conducted using WinBUGS soft-
ware (V.1.4.3, MRC Biostatistics Unit, Cambridge, UK), STATA 
software (V.11.0, Stata, College Station, Texas, USA) and Review 
Manager 5.3 software (RevMan 5.3, The Cochrane Collabora-
tion, Oxford, UK).
ResuLTs
study selection and characteristics of the included studies
Forty-three studies, comprising 36 RCTs (7900 patients with 
OA) and 7 observational studies (218 074 participants), were 
included. Figure 1 depicts the details of the selection process. 
Twelve topical therapies (ibuprofen, diclofenac patch, diclofenac 
gel, diclofenac solution, ketoprofen, eltenac, nimesulide, indo-
methacin, etoricoxib, piroxicam, salicylate and placebo) were 
evaluated for OA in the included RCTs (figure 2). The charac-
teristics of the included comparisons are shown in table 1 and 
detailed information on the included RCTs and observational 
studies is shown in online supplementary appendix 3. The meth-
odological quality was evaluated for all included trials and obser-
vational studies (online supplementary appendix 4).
effects on pain relief in RCTs (vs placebo at last follow-up 
point)
A total of 29 trials involving all 12 topical therapies were 
analysed.
Conventional meta-analysis
Topical NSAIDs overall were superior to placebo for pain relief 
(SMD=−0.30, 95% CI −0.40 to −0.20) (online supplementary 
appendix 5). Subgroup analysis further indicated that statisti-
cally significant differences were evident at weeks 1, 2, 3, 4 and 
over 4 weeks (online supplementary appendix 5). Diclofenac 
patch exhibited the largest effect for pain relief (SMD=−0.94, 
95% CI −1.20 to −0.68) (table 1).
Network meta-analysis
Diclofenac patch was most effective for pain relief (SMD=−0.81, 
95% CI −1.12 to −0.52) (figure 3). The detailed results 
are illustrated in table 2 and the rankings based on SUCRA 
are shown in online supplementary appendix 6. Diclofenac 
patch had the largest probability of being the best treat-
ment option (SUCRA=95.7%), followed by ibuprofen cream 
(SUCRA=88.81%). Network meta-regression showed that 
there were no significant interactions between pain relief and 
baseline pain level or length of follow-up time (online supple-
mentary appendix 7). There was no evidence of high hetero-
geneity among the trials (τ2=0.01). Evaluation of the goodness 
of fit demonstrated a good fit with a posterior mean residual 
Figure 1 Study selection process. ICTRP, International Clinical Trials Registry; OA, osteoarthritis; RCT, randomised controlled trials. 
Protected by copyright.
 o
n
 January 15, 2020 at G
reenfield M
edical Library Periodicals.
http://bjsm.bmj.com/
Br J Sports M
ed: first published as 10.1136/bjsports-2017-098043 on 7 February 2018. Downloaded from 
4 of 11 Zeng C, et al. Br J Sports Med 2018;52:642–650. doi:10.1136/bjsports-2017-098043
Review
deviance of 61.31 (58 data points). Subgroup analysis of studies 
with patients with knee OA and studies with efficacy data at 1 
or 2 weeks did not reveal any substantial change (online supple-
mentary appendix 8). Only one trial50 investigated the effects of 
topical diclofenac gel on patients with hand OA (SMD=−0.20, 
95% C: −0.40 to 0.00). After excluding commercially funded/
sponsored trials (17 trials), only diclofenac patch was statistically 
superior to placebo for pain relief (SMD=−0.82, 95% CI −1.65 
to −0.03) (online supplementary appendix 8).
effects on functional improvement in RCTs (vs placebo at last 
follow-up point)
A total of 27 trials involving 11 topical therapies (all except salic-
ylate) were analysed.
Conventional meta-analysis
Topical NSAIDs overall had a significantly better effect than 
placebo (SMD=−0.35, 95% CI −0.45 to −0.24) (online 
supplementary appendix 5). Subgroup analysis further indicated 
that significant differences were evident at weeks 1, 2, 3, 4 and 
over 4 weeks (online supplementary appendix 5). Piroxicam 
(SMD=−1.07, 95% CI −1.40 to −0.74) exhibited the largest 
effect for functional improvement (table 1).
Network meta-analysis
Piroxicam was the best treatment for functional improve-
ment (SMD=−1.04, 95% CI −1.60 to −0.48) (figure 3). The 
detailed results are illustrated in table 2. The ranking based 
on SUCRA is shown in online supplementary appendix 6. 
Piroxicam had the largest probability of being the best treat-
ment option (SUCRA=95.6%), followed by ibuprofen cream 
(SUCRA=84.4%) and diclofenac patch (SUCRA=72.6%). 
Network meta-regression showed no significant interactions 
between functional improvement and baseline function level or 
length of follow-up (online supplementary appendix 7). There 
was no evidence of high heterogeneity among trials (τ2=0.05). 
Evaluation of the goodness of fit demonstrated a good fit with 
a posterior mean residual deviance of 58.12 (54 data points). 
Subgroup analysis of knee OA studies and studies with efficacy 
data at 1 or 2 weeks did not reveal any substantial change (online 
supplementary appendix 8). Only one trial50 on diclofenac gel 
was restricted to patients with hand OA (SMD=−0.26, 95% CI 
−0.46 to −0.06). After excluding the trials funded/sponsored 
by commercial companies (16 trials), no active treatment was 
superior to placebo for functional improvement (online supple-
mentary appendix 8).
Adverse effects in RCTs (vs placebo at last follow-up point)
A total of 31 trials involving 11 topical therapies (all except 
etoricoxib) reported AEs.
Conventional meta-analysis
Topical NSAID s overall did not show a significantly higher risk 
for skin (OR=1.38, 95% CI 0.99 to 1.92), GI or CV AEs (online 
supplementary appendix 5). However, the withdrawal rate due 
to AE was significantly higher (OR=1.56, 95% CI 1.21 to 2.00).
Network meta-analysis
Apart from salicylate gel (OR=16.83, 95% CI 2.12 to 499.3) 
which had greater withdrawal due to AE rates compared with 
placebo, topical NSAIDs had neither more withdrawals due to 
AE nor higher incidence of AEs (such as skin, GI and CV events) 
Figure 2 Structure of network formed by interventions. The lines between treatment nodes indicate the direct comparisons made within randomised 
controlled trials. Numbers (n/n) near the line indicate ‘number of trials/number of participants’ of the related comparisons.
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(table 3). The relative safety between different topical NSAIDs 
can be seen in online supplementary appendix 8. The network 
meta-regression showed that there was no significant interac-
tion between treatment duration and AEs (online supplementary 
appendix 7). Only one RCT51 reported the risk of renal AEs 
and the results showed no significant risk of renal or urinary 
disorders associated with the use of topical ketoprofen (100, 50 
or 25 mg).
Adverse effects in observational studies
A total of seven observational studies52–58 reported AEs of 
topical NSAIDs. Conventional meta-analysis showed that 
topical NSAID users did not exhibit a significantly higher rate 
of AEs than non-users (OR=1.19, 95% CI 0.92 to 1.55) (online 
supplementary appendix 5). Three (online supplementary file 1) 
case-control studies (including a nested case-control study)52–54 
examined serious systemic AEs such as GI bleeding, perforation, 
symptomatic peptic ulcers and acute renal failure associated with 
the use of topical NSAIDs. The risks of GI bleeding (OR=1.45, 
95% CI 0.84 to 2.50), acute renal failure (OR=1.33, 95% CI 
0.79 to 2.24) and symptomatic peptic ulcers (OR=1.00, 95% CI 
0.60 to 1.70) were not significant. In addition, two case-con-
trol studies55 56 examined the photosensitivity associated with 
topical NSAIDs. One55 showed that the reporting OR for topical 
ketoprofen was 3.9 (95% CI 2.4 to 6.4) and the proportional 
reporting ratio was 3.4 (95% CI 2.1 to 5.5), versus other topical 
NSAIDs. The other56 reported that the overall population attrib-
utable risk (PAR) for severe photosensitivity reactions linked to 
topical ketoprofen was 11.92% (–0.12 to 52.99) and the PAR 
for other topical NSAIDs was 2.47% (–3.17 to 29.99). Another 
case-control study57 showed that topical NSAIDs might decrease 
the risk of squamous cell carcinoma (ever use vs non-use, inci-
dence rate ratio (IRR): 0.85, 0.76 to 0.94) and malignant mela-
noma (IRR: 0.87, 0.80 to 0.95). Finally, no AEs associated with 
topical NSAIDs were reported in the cross-sectional study.58
dIsCussIOn
This is the first network meta-analysis to take into account all 
available evidence from RCTs directly or indirectly comparing 
topical NSAIDs in OA, thereby increasing the power of the 
study. For example, although there were only two trials for 
diclofenac patch (diclofenac patch vs placebo), there were 13 
indirect comparisons (32 trials) through the network. The 
present study is also the first to summarise both RCTs and 
observational studies regarding the safety of topical NSAIDs. 
The main findings are: (1) topical NSAIDs are effective for the 
treatment of OA; (2) apart from topical salicylate acid, topical 
NSAIDs are not associated with serious GI and renal adverse 
events; (3) diclofenac patch is the most effective topical NSAIDs 
for pain relief, whereas topical piroxicam is the most effective 
topical NSAIDs for functional improvement.
Our previous conventional meta-analysis (13 RCTs) suggested 
that the efficacy of topical NSAIDs in OA only remained signif-
icant in the first 2 weeks compared with placebo.28 According 
to the NICE OA Guidelines 2014, both effect estimate and the 
related 95% CI need to be greater than 0.5 SD, corresponding 
to a 1.2 cm decrease on a 10 cm visual analogue scale, which 
was considered to be the minimal clinically important difference 
(MCID).5 Although the present conventional meta-analysis (36 
RCTs) further confirms the time-dependent effects of topical 
Table 1 Characteristics of the included comparisons in RCTs and the results of conventional meta-analysis
Comparison no. of trials no. of pts Target joint
Mean age 
(range) Female %
Mean Fu periods
(weeks, range)
sMd (95% CI) 
for pain
sMd (95% CI) 
for function
Diclofenac patch vs 
placebo
2 258 Knee 65.2 (64–67) 69.8 2 −0.94
(−1.20 to –0.68)
−0.55
(−0.81 to –0.30)
Ibuprofen vs placebo 3 225 Knee 63.9 (60.8–67) 63.5 1.3 (1–2) −0.66
(−1.06 to –0.25)
−0.72
(−1.00 to –0.44)
Piroxicam vs placebo 3 421 Knee or lumbar 51 64.5 2 −0.50
(−0.82 to –0.19)
−1.07
(−1.40 to –0.74)
Nimesulide vs placebo 1 70 Knee 53.6 84.3 4 −0.39
(−0.90 to 0.13)
−0.49
(−1.01 to 0.03)
Diclofenac gel vs 
placebo
7 1783 Multiple joints 61.3 (52–67) 69.2 6 (2–12) −0.30
(−0.39 to –0.20)
−0.36
(−0.46 to –0.27)
Diclofenac solution vs 
placebo
6 1402 Knee 62.8 (60.2–65) 63.8 7.3 (4–12) −0.29
(−0.40 to –0.18)
−0.32
(−0.43 to –0.21)
Ketoprofen vs placebo 6 2787 Knee 61.5 (59–63.3) 67.9 8 (2–12) −0.10
(−0.30 to 0.11)
−0.04
(−0.12 to 0.05)
Salicylate vs placebo 1 116 Knee or hip 65.7 55.2 4 −0.08
(−0.45 to 0.29)
NR
Eltenac vs placebo 2 437 Knee 64.5 (61–67) 72.3 4 −0.02
(−0.23 to 0.18)
−0.37
(−0.58 to –0.17)
Etoricoxib vs placebo 1 48 Knee 61.4 68.8 4 0.04
(−0.53 to 0.60)
0.13
(−0.44 to 0.69)
Indomethacin vs 
diclofenac gel
1 99 Knee, hip or hand 54.2 68.7 2 0.29
(−0.11 to 0.69)
0.38
(−0.03 to 0.78)
Indomethacin vs 
placebo
1 100 Knee or ankle NR 72 2 NR NR
Ketoprofen vs 
diclofenac gel
1 85 Knee 57.1 84.7 4 NR −0.13
(−1.48 to –0.58)
Piroxicam vs 
diclofenac gel
1 69 Knee 56.5 60.9 4 NR NR
FU, follow-up; No. of pts, number of participants included; No. of trials, number of trials included; NR, not reported; RCTs, randomised controlled trials; SMD, standardised mean 
difference.
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Figure 3 (A) Network meta-analysis of pain relief for different active interventions compared with placebo in randomised controlled trials. 
The number of trials and number of participants (pts) involved in the direct comparisons (vs placebo) were: diclofenac patch (two trials, 245 pts), 
ibuprofen (three trials, 214 pts), piroxicam (one trial, 179 pts), nimesulide (one trial, 70 pts), diclofenac gel (seven trials, 1776 pts), diclofenac solution 
(five trials, 1272 pts), ketoprofen (five trials, 2614 pts), salicylate (one trial, 114 pts), eltenac (two trials, 437 pts), indomethacin (none) and etoricoxib 
(one trial, 48 pts), and the number of trials and number of participants involved in the indirect comparisons were: diclofenac gel versus indomethacin 
(one trial, 98 pts). (B) Network meta-analysis of treatment effects on functional improvement for different active interventions compared with placebo. 
The number of trials and number of participants (pts) involved in the direct comparisons (vs placebo) were: piroxicam (one trial, 179 pts), ibuprofen 
(three trials, 211 pts), diclofenac patch (two trials, 245 pts), nimesulide (one trial, 70 pts), eltenac (two trials, 437 pts), diclofenac solution (five trials, 
1272 pts), diclofenac gel (six trials, 1657 pts), ketoprofen (four trials, 2583 pts), etoricoxib (one trial, 48 pts) and indomethacin (none). The number of 
trials and number of participants involved in the indirect comparisons was: diclofenac gel versus indomethacin (one trial, 98 pts) and diclofenac gel 
versus ketoprofen (one trial, 85 pts). SMD, standardised mean difference. 
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NSAIDs, they did not reach the MCID at any time-point (online 
supplementary appendix 5). A similar pattern was also observed 
for functional improvement (online supplementary appendix 5). 
However, care must be taken in the interpretation of this result, 
as the studies pooled at each time point were different. This 
may partially explain why there were some fluctuations/varia-
tions. Further studies to examine the wear-off effect of topical 
NSAIDs for analgesia and functional improvement in OA are 
still warranted.
Previous systematic reviews have indicated that the overall 
effect size of topical NSAIDs in the treatment of knee or hip OA 
is 0.44 (95% CI 0.27 to 0.62) for pain relief.28 59–62 However, the 
present study showed a smaller effect size (0.30, 95% CI 0.20 to 
0.40), which may be explained by the recent publication of more 
high quality RCTs. The most novel finding is that diclofenac 
patch exhibited the largest effect on pain, even above that of 
diclofenac gel and solution. This may be due to the constant 
and continuous delivery of the active ingredient to the affected 
area by means of an occlusive bandage and slow release of the 
drug when compared with traditional topical formulations such 
as gel and solution.63 64 It may also be due to the higher contex-
tual effects of patches than creams/gels.29 65 Due to the limited 
number of trials for other topical NSAIDs, we were unable to 
examine the different formulations for each topical NSAID. 
Thus more work needs to be done to confirm whether the patch 
formulation is indeed better than other formulations and what 
makes it better. Another possible explanation may be the shorter 
follow-up duration of diclofenac patch studies, as evidence 
suggests that the effects of topical NSAIDs may be gradually 
weakened with the passage of time.28 However, a subgroup anal-
ysis conducted by restricting to trials with efficacy data at 1 or 
2 weeks for all topical NSAIDs showed that diclofenac patch still 
exhibited the largest effect.
For the overall safety of topical NSAIDs, only RCT evidence 
has been systematically reviewed previously.28 59 Although 
some individual RCTs have indicated higher skin reactions in 
topical NSAIDs than in placebo, this study did not confirm 
this. This may be due to the larger sample size lowering the 
likelihood of ‘small study effects’. Another possible explana-
tion is that a higher incidence of skin AEs may be attributed 
to specific topical NSAIDs (eg, diclofenac solution, diclofenac 
gel and salicylate gel).60–62 66–69 Furthermore, there were two 
trials with significantly higher skin reactions in placebo groups 
than in active groups,70 71 which may offset the effect of topical 
NSAIDs. It should be noted that one of the studies used hyal-
uronan gel as the placebo group.70 The present study also 
found that topical NSAIDs overall exhibited a higher with-
drawal rate due to AEs than the placebo group (OR=1.56). 
After excluding the trials with salicylate gel, which were asso-
ciated with higher withdrawals due to AEs, we still observed 
a significant, but smaller AE risk (OR=1.47, 95% CI 1.15 to 
1.90).
A recent network meta-analysis that compared seven 
different oral NSAIDs for the treatment of OA found that 
diclofenac 150 mg/day was the most effective for pain and 
function.72 Several RCTs have confirmed that the clinical effi-
cacy of topical diclofenac or ibuprofen is comparable with 
their corresponding oral forms, but with better tolerability 
and safety, which support the use of topical NSAIDs ahead 
of their oral counterparts.68 73–76 In addition, the superior 
safety of topical NSAIDs in terms of GI, CV and renal risks 
has also been shown in the general population when compared 
with oral NSAIDs.52 53 77 On the basis of our findings, topical 
NSAIDs can be readily prescribed for the treatment of OA irre-
spective of common comorbidities or other medications. The 
choice of topical NSAID may be made according to the order 
presented in figure 3. The order should be based on both the 
SMD and its 95% CI and diclofenac patch is, therefore, the 
first line topical NSAID.
There are several caveats to this study. First, the number 
of RCTs for some topical NSAIDs is relatively small, espe-
cially in hand OA. Second, although the present study indi-
cated that overall topical NSAIDs were effective and safe for 
OA, diclofenac patch was the most effective and only topical 
NSAID to reach the MCID in pain relief. Third, most of the 
follow-up periods of the included studies were relatively short, 
only examined the short (1–6 weeks) and medium-term (6–12 
weeks) efficacy and safety of topical NSAIDs in RCTs. This is 
problematic for safety profiles as it is not possible to measure 
long-term outcomes for drug safety, such as GI and CV events. 
We, therefore, included the observational studies to overcome 
this limitation. Fourth, we only identified seven observational 
studies (218 074 participants) for the assessment of the safety 
of topical NSAIDs in the real world setting, irrespective of 
the target condition. A population-based and well-controlled 
cohort study is still needed to confidently determine a causal 
relationship between topical NSAIDs and AEs, especially CV 
AEs in people with OA. Fifth, like other meta-analyses, hetero-
geneity may affect the results of this meta-analysis. Last but 
not least, after excluding industry-funded/sponsored trials, 
Table 3 Adverse effects of different topical NSAIDs compared with 
placebo according to network meta-analysis in RCTs
Treatment OR (95% CI) suCRA (%)
Skin AE
  Placebo Reference 62.0
  Diclofenac gel   1.58 (0.58 to 4.87) 39.8
  Diclofenac solution   1.78 (0.79 to 4.08) 34.1
  Diclofenac patch   0.94 (0.11 to 7.11) 57.6
  Ketoprofen   1.17 (0.48 to 2.96) 52.8
  Eltenac   1.19 (0.20 to 6.57) 51.0
  Ibuprofen   0.93 (0.02 to 62.38) 54.4
  Nimesulide   1.14 (0.05 to 58.10) 50.5
  Salicylate   5.34 (0.68 to 43.38) 12.8
  Piroxicam   1.49 (0.34 to 7.11) 43.2
  Indomethacin   0.07 (0.00 to 2.37) 92.0
GI AE
  Placebo Reference 45.3
  Diclofenac gel   1.25 (0.52 to 2.59) 30.1
  Diclofenac solution   0.99 (0.54 to 1.86) 46.3
  Diclofenac patch   0.99 (0.06 to 23.14) 47.9
  Ketoprofen   0.82 (0.41 to 1.64) 62.2
  Eltenac   0.62 (0.14 to 2.86) 69.6
  Salicylate   0.97 (0.21 to 4.54) 48.5
Withdrawal due to AE
  Placebo Reference 78.0
  Diclofenac gel   1.93 (0.94 to 3.91) 38.8
  Diclofenac solution   1.43 (0.73 to 2.86) 54.2
  Diclofenac patch   0.47 (0.03 to 3.70) 85.9
  Ketoprofen gel   1.40 (0.80 to 2.55) 54.8
  Eltenac gel   1.27 (0.11 to 35.04) 57.3
  Salicylate gel   16.83 (2.12 to 499.3) 37.5
  Indomethacin   3.22 (0.63 to 17.43) 27.2
AE, adverse effect; GI, gastrointestinal; RCTs, randomised controlled trials; SUCRA, 
surface under the cumulative ranking.
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only diclofenac patch was statistically superior to placebo for 
pain relief and none of the topical NSAIDs was better than 
placebo for functional improvement. This suggests that the 
efficacy of topical NSAIDs may be inflated by industry involve-
ment. However, the limited number of remaining non-indus-
try-funded/sponsored trials (only 12 trials for pain relief and 
11 trials for functional improvement) may be too small to 
detect the difference, as these trials were small (ranging from 
31 to 179 participants, median size 100). Further non-in-
dustry-funded/sponsored trials for topical NSAIDs are still 
needed, as this is a group of drugs with greater contextual 
effect than their oral counterparts29 and it is more difficult to 
blind participants in trials and hence very easy to inflate their 
treatment benefits over placebo. We also attempted to examine 
whether trials with ≥100 participants per arm would give a 
different conclusion but failed as only 13 trials which fulfilled 
this criterion.
COnCLusIOn
This systematic review identified 43 studies, comparing 36 
RCTs (7900 patients with OA at any joint) and 7 observa-
tional studies (218 074 participants). Topical NSAIDs reduced 
pain and improved function in patients with OA. Diclofenac 
patches were the most effective topical NSAID for pain relief. 
No serious AEs were observed in randomised trials or observa-
tional studies in the general population. However, confirma-
tion of the CV safety of topical NSAIDs still warrants further 
observational study.
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